Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:atccode |
J05 AE09
|
| gptkbp:can_be_combined_with |
gptkb:Pibrentasvir
|
| gptkbp:casnumber |
1256580-50-0
|
| gptkbp:chemical_formula |
C20 H25 N5 O4 S
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| https://www.w3.org/2000/01/rdf-schema#label |
Glecaprevir
|
| gptkbp:interacts_with |
gptkb:atazanavir
gptkb:efavirenz gptkb:St._John's_Wort gptkb:carbamazepine gptkb:rifampin |
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
NS3/4 A protease inhibitor
|
| gptkbp:side_effect |
fatigue
headache nausea |
| gptkbp:trade |
gptkb:Mavyret
|
| gptkbp:used_for |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:Mavyret
|
| gptkbp:bfsLayer |
6
|